2013
Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial
Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO, O’Connor C, Felker GM, Goldsmith SR, Bart B, McNulty SE, Ibarra JC, Lin G, Oh JK, Patel MR, Kim RJ, Tracy RP, Velazquez EJ, Anstrom KJ, Hernandez AF, Mascette AM, Braunwald E, Trial F. Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial. JAMA 2013, 309: 1268-1277. PMID: 23478662, PMCID: PMC3835156, DOI: 10.1001/jama.2013.2024.Peer-Reviewed Original ResearchConceptsPeak oxygen consumptionPhosphodiesterase-5 inhibitionExercise capacityWalk distanceEjection fractionHeart failureClinical statusPlacebo patientsAdverse eventsClinical trialsFilling pressureN-terminal brain-type natriuretic peptideElevated left ventricular filling pressureMedian peak oxygen consumptionPulmonary artery systolic pressureLeft ventricular filling pressureBrain-type natriuretic peptidePhosphodiesterase-5 inhibitor sildenafilEnd pointOxygen consumptionPrimary end pointSecondary end pointsVentricular filling pressureWeek 24 dataWeeks of therapy
2008
Emerging Role of Myocardial Perfusion Imaging to Evaluate Patients for Cardiac Resynchronization Therapy††Conflicts of interest: Dr. Garcia has an ownership interest in and serves as a consultant and advisory board member for Syntermed, Inc., Atlanta, Georgia. Dr. Garcia also receives royalties from the sale of clinical software that was used as part of this research. Dr. Borges-Neto and Dr. Trimble have received research support from the Duke-Medtronic Strategic Alliance, which funded some of the studies reviewed in this report.
Trimble MA, Borges-Neto S, Velazquez EJ, Chen J, Shaw LK, Pagnanelli R, Garcia EV, Iskandrian AE. Emerging Role of Myocardial Perfusion Imaging to Evaluate Patients for Cardiac Resynchronization Therapy††Conflicts of interest: Dr. Garcia has an ownership interest in and serves as a consultant and advisory board member for Syntermed, Inc., Atlanta, Georgia. Dr. Garcia also receives royalties from the sale of clinical software that was used as part of this research. Dr. Borges-Neto and Dr. Trimble have received research support from the Duke-Medtronic Strategic Alliance, which funded some of the studies reviewed in this report. The American Journal Of Cardiology 2008, 102: 211-217. PMID: 18602524, DOI: 10.1016/j.amjcard.2008.03.043.Peer-Reviewed Original ResearchConceptsCardiac resynchronization therapyMechanical dyssynchronyElectrical dyssynchronyMyocardial perfusionSignificant heart failure symptomsTomographic myocardial perfusion imagingLV functional improvementHeart failure symptomsLV systolic dysfunctionSevere LV dysfunctionSelection of patientsManagement of patientsLV mechanical dyssynchronyLeft ventricular dyssynchronyMyocardial perfusion imagingCurrent selection criteriaLV dysfunctionSystolic dysfunctionEchocardiographic measuresResynchronization therapyVentricular dyssynchronyCardiac resynchronizationClinical statusLV remodelingFailure symptoms